Cytochrome P450 2D6 Genotype on the Clinical Effect of Carvedilol

Phase 1 Completed 24 enrolled Seoul National University Hospital National Institute of Food and Drug Safety Evaluation, Korea · collab

NaSingle-groupOpen-labelTreatment

Summary

A Clinical Study to Evaluate the Effect of Cytochrome P450 2D6 polymorphism on Pharmacokinetics/Pharmacodynamics After Multiple Administration of Carvedilol

Timeline

Start: 2014-09
Primary completion: 2014-11
Completion: 2014-12

Publications

Jung E, Ryu S, Park Z, Lee JG, Yi JY, Seo DW, Lee J, Jeong HS, Kim JM, Oh WY. Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers. J Korean Med Sci. 2018 May 23;33(27):e182. doi: 10.3346/jkms.2018.33.e182. eCollection 2018 Jul 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carvedilol	Other / unclassified	25 mg	Oral

Indications

No indication recorded.